Nextbiomedical넥스트바이오메디컬
389650 · KOSDAQ · ₩389650 · 넥스트바이오메디컬
₩28,350▼ ₩950 (3.24%)End-of-day · Oct 29, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | |
|---|---|---|
| Revenue | ₩16B | ₩9.5B |
| Cost of sales | ₩4.9B | ₩3.7B |
| Gross profit | ₩12B | ₩5.8B |
| Operating income | −₩720M | −₩3.6B |
| Net income | −₩311M | ₩2.9B |
| Net income to shareholders | −₩311M | ₩2.9B |
Balance sheet
| 2025 | 2024 | |
|---|---|---|
| Total assets | ₩59B | ₩59B |
| Current assets | ₩43B | ₩47B |
| Cash and equivalents | ₩6.8B | ₩5B |
| Total liabilities | ₩11B | ₩14B |
| Current liabilities | ₩8B | ₩12B |
| Borrowings | ₩951M | ₩764M |
| Total equity | ₩48B | ₩45B |
| Shareholders' equity | ₩48B | ₩45B |
Cash flow
| 2025 | 2024 | |
|---|---|---|
| Cash from operations | ₩1.3B | −₩1.2B |
| Capital spending | ₩3.2B | ₩439M |
| Free cash flow | −₩1.9B | −₩1.6B |
Consolidated where available. Amounts in won.
Also known as: Nextbiomedical / 넥스트바이오메디컬 / 389650 / KRX:389650
Source: KRX statistical information